Abbott Seals $23B Exact Sciences Deal, Forging a Cancer Diagnostics Giant

MADISON, WI – February 20, 2026 – Exact Sciences stockholders have overwhelmingly approved the company's proposed acquisition by healthcare giant Abbott, a decisive step in creating a new powerhouse in the rapidly expanding cancer diagnostics market. The vote, announced today following a special stockholder meeting, clears a major hurdle for the approximately $23 billion enterprise value transaction that promises to reshape how cancer is detected and treated.

Preliminary results show that an overwhelming 99% of votes cast were in favor of the deal. This represents about 67% of all outstanding shares, demonstrating strong support for the acquisition, which will see stockholders receive $105.00 in cash for each share of Exact Sciences common stock they own. The transaction is now on track to close before the end of the second quarter of 2026, pending final regulatory approvals and other customary closing conditions.

A Strategic Gambit for Market Dominance

For Abbott, a diversified healthcare company with a massive global footprint, the acquisition is a bold and strategic entry into the high-growth field of oncology testing. The move is widely seen as an effort to establish a commanding presence in cancer diagnostics and offset recent revenue declines from its once-booming COVID-19 testing business.

The integration of Exact Sciences is expected to more than double Abbott's total addressable market in diagnostics to over $120 billion and boost its annual diagnostics revenue to more than $12 billion. Abbott CEO Robert Ford previously lauded Exact Sciences' innovation and customer focus as "unrivaled," calling the combination a pivotal step in defining the "next era in diagnostics," centered on prevention and personalization.

By acquiring Exact Sciences, Abbott gains a portfolio of market-leading and pipeline products that cover the entire cancer care continuum. This includes the well-established Cologuard noninvasive colorectal cancer screening test, the Oncotype DX tests for guiding breast cancer treatment, and a promising pipeline featuring Cancerguard, a multi-cancer early detection test, and Oncodetect for monitoring disease recurrence. The deal is projected to add approximately 300 basis points to the growth rate of Abbott's Diagnostics segment and significantly enhance its gross margin profile.

A Lucrative Exit and Sector Validation

The financial terms of the deal underscore the high stakes and immense value placed on innovation in the diagnostics sector. The $105.00 per-share price represents a substantial 51% premium over Exact Sciences' closing price on the day before news of the potential deal first surfaced in November 2025. This premium fueled a significant rally in Exact Sciences' stock, while Abbott's shares saw a modest dip, a typical reaction for an acquiring company in a large transaction.

Market analysts have described the acquisition as a "sector defining event," validating the business models of specialized diagnostics firms and potentially signaling that the broader sector is undervalued. While the deal is projected to be slightly dilutive to Abbott's earnings per share in the first two years, it is expected to become accretive thereafter, with the company anticipating a return to double-digit EPS growth by 2027. Abbott also projects achieving around $100 million in annual synergies after the acquisition is complete.

The stockholder vote itself, while overwhelmingly positive on the merger, offered a nuanced detail: an advisory proposal on merger-related executive compensation did not pass. This non-binding vote, while having no impact on the deal's closure, reflects a pocket of shareholder sentiment on the executive payout structure, a common point of contention in major corporate acquisitions.

Accelerating the Future of Early Detection

Beyond the corporate strategy and financial metrics, the acquisition holds profound implications for patients and public health. The combination of Exact Sciences' cutting-edge diagnostic platforms with Abbott's vast global infrastructure, manufacturing expertise, and commercial reach is expected to dramatically accelerate the development and accessibility of life-saving tests.

Exact Sciences has been a pioneer in making cancer screening more accessible with its at-home Cologuard test. Now, with Abbott's backing, the potential to scale up distribution and navigate complex international regulatory environments for its entire portfolio is significantly enhanced. This is particularly crucial for its pipeline products like Cancerguard, which aims to detect multiple types of cancer from a single blood draw—a technology that could revolutionize oncology.

In a statement from the original announcement, Exact Sciences Chairman and CEO Kevin Conroy noted that Abbott's global reach would be instrumental in broadening access to their tests and fostering continued advancements. This sentiment points to a future where earlier, more accurate, and more personalized diagnostics become the standard of care worldwide, helping to "find cancers earlier and matching patients to the right treatments."

As the deal moves toward its final closure, the healthcare industry will be watching closely. Exact Sciences is set to operate as a subsidiary of Abbott, maintaining its headquarters and significant presence in Madison, Wisconsin. Kevin Conroy will remain in an advisory role to help guide the integration, ensuring that the innovative spirit that defined Exact Sciences continues to thrive within its new, larger home. The successful union of these two companies could mark a significant turning point in the global fight against cancer.